Logo image of NMTC

NEUROONE MEDICAL TECHNOLOGIE (NMTC) Stock Fundamental Analysis

NASDAQ:NMTC - Nasdaq - US64130M2098 - Common Stock - Currency: USD

0.6099  +0.05 (+8.52%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NMTC. NMTC was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NMTC has a bad profitability rating. Also its financial health evaluation is rather negative. NMTC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NMTC has reported negative net income.
NMTC had a negative operating cash flow in the past year.
In the past 5 years NMTC always reported negative net income.
NMTC had a negative operating cash flow in each of the past 5 years.
NMTC Yearly Net Income VS EBIT VS OCF VS FCFNMTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

NMTC has a Return On Assets of -148.22%. This is amonst the worse of the industry: NMTC underperforms 89.84% of its industry peers.
Looking at the Return On Equity, with a value of -586.72%, NMTC is doing worse than 89.30% of the companies in the same industry.
Industry RankSector Rank
ROA -148.22%
ROE -586.72%
ROIC N/A
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
NMTC Yearly ROA, ROE, ROICNMTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K -2K

1.3 Margins

NMTC has a Gross Margin of 69.88%. This is amongst the best in the industry. NMTC outperforms 80.75% of its industry peers.
The Profit Margin and Operating Margin are not available for NMTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMTC Yearly Profit, Operating, Gross MarginsNMTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NMTC has been increased compared to 1 year ago.
Compared to 5 years ago, NMTC has more shares outstanding
Compared to 1 year ago, NMTC has a worse debt to assets ratio.
NMTC Yearly Shares OutstandingNMTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NMTC Yearly Total Debt VS Total AssetsNMTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

NMTC has an Altman-Z score of -21.04. This is a bad value and indicates that NMTC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -21.04, NMTC is not doing good in the industry: 89.84% of the companies in the same industry are doing better.
NMTC has a Debt/Equity ratio of 1.21. This is a high value indicating a heavy dependency on external financing.
NMTC's Debt to Equity ratio of 1.21 is on the low side compared to the rest of the industry. NMTC is outperformed by 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Altman-Z -21.04
ROIC/WACCN/A
WACC8.86%
NMTC Yearly LT Debt VS Equity VS FCFNMTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 2.13 indicates that NMTC has no problem at all paying its short term obligations.
The Current ratio of NMTC (2.13) is worse than 62.57% of its industry peers.
A Quick Ratio of 1.09 indicates that NMTC should not have too much problems paying its short term obligations.
NMTC's Quick ratio of 1.09 is on the low side compared to the rest of the industry. NMTC is outperformed by 74.33% of its industry peers.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 1.09
NMTC Yearly Current Assets VS Current LiabilitesNMTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.44% over the past year.
NMTC shows a strong growth in Revenue. In the last year, the Revenue has grown by 132.49%.
The Revenue has been growing by 143.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)61.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)132.49%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%0.72%

3.2 Future

NMTC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.68% yearly.
NMTC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.68% yearly.
EPS Next Y66.67%
EPS Next 2Y27.24%
EPS Next 3Y19.68%
EPS Next 5YN/A
Revenue Next Year16.57%
Revenue Next 2Y27.23%
Revenue Next 3Y31.56%
Revenue Next 5Y34.68%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NMTC Yearly Revenue VS EstimatesNMTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 5M 10M 15M 20M
NMTC Yearly EPS VS EstimatesNMTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NMTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NMTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMTC Price Earnings VS Forward Price EarningsNMTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMTC Per share dataNMTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as NMTC's earnings are expected to grow with 19.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.24%
EPS Next 3Y19.68%

More info and screens

0

5. Dividend

5.1 Amount

NMTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROONE MEDICAL TECHNOLOGIE

NASDAQ:NMTC (6/16/2025, 1:07:36 PM)

0.6099

+0.05 (+8.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-12 2025-08-12/amc
Inst Owners10.96%
Inst Owner Change19.2%
Ins Owners4.26%
Ins Owner Change4.39%
Market Cap30.39M
Analysts85.71
Price Target1.48 (142.66%)
Short Float %0.43%
Short Ratio0.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)91.29%
Min EPS beat(2)23.75%
Max EPS beat(2)158.82%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.72%
Min Revenue beat(2)-43.22%
Max Revenue beat(2)52.66%
Revenue beat(4)1
Avg Revenue beat(4)-34.64%
Min Revenue beat(4)-88.49%
Max Revenue beat(4)52.66%
Revenue beat(8)3
Avg Revenue beat(8)-9.26%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-53.97%
EPS NQ rev (1m)28.57%
EPS NQ rev (3m)28.57%
EPS NY rev (1m)0%
EPS NY rev (3m)50%
Revenue NQ rev (1m)-42.59%
Revenue NQ rev (3m)-42.59%
Revenue NY rev (1m)-38.65%
Revenue NY rev (3m)-38.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.47
P/FCF N/A
P/OCF N/A
P/B 26.99
P/tB 28.4
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.18
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -148.22%
ROE -586.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.88%
FCFM N/A
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.97
Health
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.2%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.13
Quick Ratio 1.09
Altman-Z -21.04
F-Score4
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)158.25%
Cap/Depr(5y)160.45%
Cap/Sales(3y)9.28%
Cap/Sales(5y)12.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y66.67%
EPS Next 2Y27.24%
EPS Next 3Y19.68%
EPS Next 5YN/A
Revenue 1Y (TTM)132.49%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%0.72%
Revenue Next Year16.57%
Revenue Next 2Y27.23%
Revenue Next 3Y31.56%
Revenue Next 5Y34.68%
EBIT growth 1Y49.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.65%
OCF growth 3YN/A
OCF growth 5YN/A